An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin

BioDrugs

Volumn 29, Issue 4, 2015, Pages 285-300

  Gianoncelli, Alessandra ^a   Bonini, Sara A ^a   Bertuzzi, Michela ^a   Guarienti, Michela ^a   Vezzoli, Sara ^a   Kumar, Rajesh ^a   Delbarba, Andrea ^a   Mastinu, Andrea ^a   Sigala, Sandra ^a   Spano, Pierfranco ^a   Pani, Luca ^b   Pecorelli, Sergio ^a,b   Memo, Maurizio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b ITALIAN MEDICINES AGENCY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; NERVE GROWTH FACTOR; PROTEIN; RECOMBINANT ERYTHROPOIETIN; STEM CELL FACTOR; TRYPSIN; TUMOR NECROSIS FACTOR ALPHA; ANTIANEMIC AGENT; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; DRUG STRUCTURE; EMBRYO; ERYTHROCYTE; GRANULOCYTE; IN VITRO STUDY; MACROPHAGE; MASS FRAGMENTOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; ZEBRA FISH; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG APPROVAL; DRUG EFFECTS; EMBRYOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; PROCEDURES; QUALITY CONTROL; REVERSED PHASE LIQUID CHROMATOGRAPHY; STANDARDS;

AMINO ACID SEQUENCE; ANIMALS; BIOSIMILAR PHARMACEUTICALS; CELL PROLIFERATION; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DRUG APPROVAL; EPOETIN ALFA; HEMATINICS; HUMANS; QUALITY CONTROL; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; ZEBRAFISH;

EID: 84941425068     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-015-0136-3     Document Type: Article

References (46)

1. Epstain MS, Ehrenpreis ED, Kulkarni PM, FDA-Related Matters Committee of the American College of Gastroenterology. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 2014;109:1856-9.
2. European Medicines Agency. Biological medicinal products. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/Brochure/2011/03/WC500104227.pdf. Accessed 26 May 2015.
3. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf. Accessed 26 May 2015.
4. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). EMA/CHMP/BWP/247713/2012. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/06/WC500167838.pdf. Accessed 26 May 2015.
5. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 Rev1. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219.pdf. Accessed 26 May 2015.
6. Abraham I, Han L, Sun D, MacDonald K, Aapro M. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol. 2014;10(9):1599-609. doi: 10.2217/fon.14.43.
7. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191-6. doi: 10.1182/blood-2014-06-583617.
8. Bocquet F, Paubel P, Fusier I, Cordonnier AL, Sinègre M, Le Pen C. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience. Appl Health Econ Health Policy. 2015;13(1):47-59. doi: 10.1007/s40258-014-0125-6.
9. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527-40. doi: 10.1038/nrd3746.
10. Krantz SB. Erythropoietin. Blood. 1991;77:419-34.
11. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Seehra J, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806-10. doi: 10.1038/313806a0.
12. Research and Markets. Erythropoietin market forecast to 2015. http://www.researchandmarkets.com/research/h68rlt/erythropoietin-mar. Accessed 26 May 2015.
13. Gong B, Burnina I, Stadhein TA, Li H. Glycosylation characterization of recombinant human erythropoietin produced in glycoengineered Pichia pastoris by mass spectrometry. J Mass Spectrom. 2013;48(12):1308-17. doi: 10.1002/jms.3291.
14. Takeuchi M, Takasaki S, Miyazaki H, Kato T, Hoshi S, Kochibe N, et al. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem. 1988;263:3657-63.
15. Dube S, Fisher JW, Powell JS. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem. 1988;263:17516-21.
16. Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood. 1989;73:84-9.
17. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood. 2001;8(13):3626-34. doi: 10.1182/blood.V98.13.3626.
18. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol. 2004;32(12):1146-55. doi: 10.1016/j.exphem.2004.08.004.
19. Mikhail A, Farouk M. Epoetin biosimilars in Europe: five years on. Adv Ther. 2013;30(1):28-40. doi: 10.1007/s12325-012-0072-2.
20. EMA. Epoetin alfa: EPAR - Scientific discussion. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000725/WC500053615.pdf. Accessed 22 Jan 2015.
21. EMA. Retacrit: EPAR - Scientific discussion. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000872/WC500054374.pdf. Accessed 22 Jan 2015.
22. Stenerson KK. The derivatization and analysis of amino acids by GC-MS. Reporter US Volume 25.3. Sigma-Aldrich. https://www.sigmaaldrich.com/content/dam/sigma-aldrich/articles/reporter-us/pdf/the-derivatization.pdf. Accessed 17 Aug 2015.
23. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996;68(5):850-8. doi: 10.1021/ac950914h.
24. Schiarea S, Solinas G, Allavena P, Scigliuolo GM, Bagnati R, Fanelli R, et al. Secretome analysis of multiple pancreatic cancer cell lines reveals perturbations of key functional networks. J Proteome Res. 2010;9:4376-92.
25. Westerfield M. The zebrafish book. A guide for the laboratory use of zebrafish (Daniorerio). 4th ed. Eugene: University of Oregon Press; 2000.
26. Isogai S, Horiguchi M, Weinstein BM. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev Biol. 2001;230(2):278-301. doi: 10.1006/dbio.2000.9995.
27. Chu CY, Cheng CH, Chen GD, Chen YC, Hung CC, Huang KY, et al. The zebrafish erythropoietin: functional identification and biochemical characterization. FEBS Lett. 2007;581(22):4265-71. doi: 10.1016/j.febslet.2007.07.073.
28. Kwan TT, Liang R, Verfaillie CM, Ekker SC, Chan LC, Lin S, et al. Regulation of primitive hematopoiesis in zebrafish embryos by the death receptor gene. Exp Hematol. 2006;34(1):27-34. doi: 10.1016/j.exphem.2005.09.017.
29. Le Guyader D, Redd MJ, Colucci-Guyon E, Murayama E, Kissa K, Briolat V, et al. Origins and unconventional behavior of neutrophils in developing zebrafish. Blood. 2008;111(1):132-41. doi: 10.1182/2007-06-095398.
30. Thisse C, Thisse B. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc. 2008;3(1):59-69. doi: 10.1038/nprot.2007.514.
31. Stanley SMR, Poljak A. Matrix-assisted laser-desorption time-of flight ionisation and high-performance liquid chromatography-electrospray ionisation mass spectral analyses of two glycosylated recombinant epoetins. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;785(2):205-18. doi: 10.1016/S1570-0232(02)00824-3.
32. Reichel C, Thevis M. Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin. Bioanalysis. 2013;5(5):587-602. doi: 10.4155/BIO.13.9.
33. ExPASy. Bioinformatics Resource Portal. http://www.expasy.org/proteomics. Accessed 26 May 2015.
34. Baldwin MA. Protein identification by mass spectrometry - issues to be considered. Mol Cell Proteomics. 2004;3(1):1-9. doi: 10.1074/mcp.R300012-MCP200.
35. Atwood JA 3rd, Sahoo SS, Alvarez-Manilla G, Weatherly DB, Kolli K, Orlando R, et al. Simple modification of a protein database for mass spectral identification of N-linked glycopeptides. Rapid Commun Mass Spectrom. 2005;19(21):3002-6. doi: 10.1002/rcm.2162.
36. Kawasaki N, Ohta M, Hyuga S, Hyuga M, Hayakawa T. Application of liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin. Anal Biochem. 2000;285(1):82-91. doi: 10.1006/abio.2000.4739.
37. Tarentino AL, Gomez CM, Plummer TH. Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase-F. Biochemistry. 1985;24(17):4665-71. doi: 10.1021/bi00338a028.
38. Brinks V, Hawe A, Basmeleh AHH, Joachin-Rodriguez L, Haselberg R, Somsen GW, et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28(2):386-93. doi: 10.1007/s11095-010-0288-2.
39. Caldini A, Moneti G, Fanelli A, Bruschettini A, Mercurio S, Pieraccini G, et al. Epoetin alfa, epoetin beta and darbepoetin alfa: two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis. Proteomics. 2003;3(6):937-41. doi: 10.1002/pmic.200300405.
40. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyacawa K, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol. 1989;140(2):323-34. doi: 10.1002/jcp.1041400219.
41. Winter SS, Howard T, Ware RE. Regulation of expression of the human erythropoietin receptor gene. Blood Cell Mol Dis. 1996;22(3):214-24. doi: 10.1006/bcmd.1996.0102 (discussion 224a).
42. Miresluis AR, Page L, Thorpe R. Quantitative cell line based bioassays for human cytokines. J Immunol Methods. 1995;187(2):191-9. doi: 10.1016/0022-1759(95)00220-1.
43. Testa U, Grignani F, Hassan HJ, Rogaia D, Masciulli R, Gelmetti V, et al. Terminal megakaryocytic differentiation of TF-1 cells is induced by phorbol esters and thrombopoietin and is blocked by expression of PML/RAR alfa fusion protein. Leukemia. 1998;12(4):563-70. doi: 10.1038/sj.leu.2400967.
44. Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. BioEssays. 2003;25(9):904-12. doi: 10.1002/bies.10326.
45. Jing L, Zon LI. Zebrafish as a model for normal and malignant hematopoiesis. Dis Model Mech. 2011;4(4):433-8. doi: 10.1242/dmm.006791.
46. Chen AT, Zon LI. Zebrafish blood stem cells. J Cell Biochem. 2009;108(1):35-42. doi: 10.1002/jcb.22251.